Blood Loss at the Time of First Trimester Surgical Abortion in Anticoagulated Women

This study has been completed.
Sponsor:
Collaborator:
Oregon Health and Science University
Information provided by:
University of Hawaii
ClinicalTrials.gov Identifier:
NCT00614432
First received: January 31, 2008
Last updated: December 16, 2010
Last verified: December 2010
  Purpose

The primary objective of this study is to compare blood loss resulting from surgical termination of pregnancy up to 12 weeks gestation between women who are anticoagulated to therapeutic levels and those who are not anticoagulated. This study is based on the hypothesis that anticoagulant therapy does not increase intraoperative blood loss in women receiving surgical abortions up to 12 weeks gestation.


Condition
Blood Loss

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Blood Loss at the Time of First Trimester Surgical Abortion in Anticoagulated Women

Resource links provided by NLM:


Further study details as provided by University of Hawaii:

Primary Outcome Measures:
  • Differences is intraoperative blood loss in anticoagulated versus non-anticoagulated women receiving a surgical termination of pregnancy. [ Time Frame: Post procedure ] [ Designated as safety issue: Yes ]

Biospecimen Retention:   Samples Without DNA

Whole blood


Estimated Enrollment: 30
Study Start Date: January 2008
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Women who are anticoagulated.
2
Matched case controls.

Detailed Description:

We intend to conduct a prospective cohort study at Oregon Health and Science University and the University of Hawaii. This study will not be blinded and subjects will not be randomized. Women will be approached about this study after they have made a decision to terminate the pregnancy and have completed the preoperative history and physical examination and surgical consenting process. For patients who are receiving anticoagulant medications, the decision to continue anticoagulant therapy or interrupt it will be made by the patient's physician, independently of this study.

We will recruit women who continue on anticoagulant therapy (heparin, low molecular weight heparin, or warfarin) without interruption for the surgical procedure. Our control group will consist of women who are not on anticoagulant treatment. This is a matched study and our control group will be matched for gestational age, parity, and cesarean section history.

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Women will be approached about this study after they have made a decision to terminate the pregnancy and have completed the preoperative history and physical examination and surgical consenting process. We will recruit women who continue on anticoagulant therapy (heparin, low molecular weight heparin, or warfarin) without interruption for the surgical procedure. Our control group will consist of women who are not on anticoagulant treatment.

Criteria

Inclusion Criteria:

  • Female seeking abortion services
  • Less than or equal to 12 weeks gestation
  • Age 18-50
  • Willing and able to sign informed consent
  • Use of Coumadin or LMW heparin (treatment group only)

Exclusion Criteria:

  • Unwilling or unable to sign informed consent
  • Women taking daily aspirin or herbal therapies containing gingko biloba
  • Women with a known history of a bleeding disorder such as von willebrand's disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00614432

Locations
United States, Hawaii
University of Hawaii
Honolulu, Hawaii, United States, 96822
United States, Oregon
Oregon Health and Science University
Portland, Oregon, United States, 97239
Sponsors and Collaborators
University of Hawaii
Oregon Health and Science University
Investigators
Principal Investigator: Bliss Kaneshiro, M.D. University of Hawaii
Principal Investigator: Alison Edelman, M.D., M.P.H. Oregon Health and Science University
  More Information

No publications provided

Responsible Party: Bliss Kaneshiro, MD, University of Hawaii
ClinicalTrials.gov Identifier: NCT00614432     History of Changes
Other Study ID Numbers: OHSU FAMPLAN 3861
Study First Received: January 31, 2008
Last Updated: December 16, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by University of Hawaii:
anticoagulation
surgical abortion

Additional relevant MeSH terms:
Hemorrhage
Pathologic Processes

ClinicalTrials.gov processed this record on October 19, 2014